Lilly
Menu closed
Lilly
  • For Patients
    • ALIMTA® (pemetrexed for injection)
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Retevmo® (selpercatinib)
    • Verzenio Continuous Care™ Support Program
  • For Healthcare Providers
    • Support and Resources
  • Contact Us
Globe Loading... Reveal available languages

Lilly Oncology Support Center Sitemap

For Patients

For Patients Home

  • ALIMTA® (pemetrexed for injection)
  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Retevmo® (selpercatinib)
  • Verzenio Continuous Care™ Support Program

For Healthcare Providers

For Healthcare Providers Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Retevmo® (selpercatinib)
  • Verzenio® (abemaciclib)
  • Support and Resources

Contact Us

Prescribing Information for ALIMTA® (pemetrexed for injection)
Patient Prescribing Information for ALIMTA® (pemetrexed for injection)
Prescribing Information for CYRAMZA® (ramucirumab)
Prescribing Information for ERBITUX® (cetuximab), including BOXED WARNING
Prescribing Information for Retevmo® (selpercatinib)
Patient Prescribing Information for Retevmo® (selpercatinib)
Prescribing Information for Verzenio® (abemaciclib)
Patient Prescribing Information for Verzenio® (abemaciclib)
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap

To speak to customer support:
Call 1-866-472-8663
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0369 11/2022 ©Lilly USA, LLC 2022. All rights reserved.

ALIMTA®, CYRAMZA®, ERBITUX®, Retevmo®, and Verzenio® are registered trademarks and Verzenio Continuous Care™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Other product/company names mentioned herein are the property of their respective owners.

Terms of UsePrivacy StatementAccessibility StatementSitemap
Lilly